Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > SO IM MISSING THE GOOD NEWS

<< Previous

Bullboard Posts

Next >>

Comment by Oden6570on Aug 13, 2024 7:02am

117 Views

Post# 36175991

RE:RE:RE:SO IM MISSING THE GOOD NEWS

CancerSlayer wrote:
Beano349 wrote: The good news was the new 450 CR tracking of over 40%. 1 treatment, and a CR over 40 over 1 year later. That's a big deal, but we still need approval...

Good news today...

To be clear, a DOR% is different than a CR% at a given point in time. A DOR% refers to the % of responders who have maintained their response over a given period or "duration" of time. A CR% reflects the total number of responders out of the total number treated at any given "point" in time.

The 44% 450 day number reported is referring to a DOR % (of the 41 responders, 18 maintained a response for 360 days). The 450 day CR would be 18 out of a total of 65 patients treated (or ~28% CR at 450 days). Per the swimmer's plot, there are 18 patients who have passed the 540 day mark, 2 of whom were determined to have recurrent high-grade NMIBC. The remaining 16 include 5 responders & 11 who have pending data.

The encouraging news for me is that of the 7 patients who have undergone evaluation (after 540 days), 5 of 7 (71%) continued to show CR at 690+ days, indicating a promising durable response based on this small subset. There are also 2 patients who are pre-360 day follow-up...one being IR & the other a CR.

Based on my rudimentary math/extrapolation, if all goes well with the above 11 pending patients, I'd estimate that ~8 of 11 patients would have a good chance of maintaining their CR for at least 24 months. This would give a total of 13 patients maintaining a 24+ month response out of a total of 65 treated (20% CR), which would actually beat Keytruda's "12" month CR (~19%). The 2 pre-360 day patients could potentially bump up our 24 month CR to 21-23%.

Our current data suggest that this company's therapeutic success as a monotherapy will not only exceed all other monotherapies available, but also rival any combined therapy currently under evaluation or recently approved. All imo. Good luck...